https://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-milestone-for-treatment-of-deadly-diseaseContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-milestone-for-treatment-of-deadly-diseasehttps://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-milestone-for-treatment-of-deadly-disease#u51245Sat, 29 Aug 2026 03:06:34 +0000The FDA has approved Rasonque, a once-daily pill from Revolution Medicines, for treating advanced pancreatic cancer. The drug targets the RAS protein, which drives 95% of pancreatic adenocarcinoma cases. Rasonque provides a treatment option for patients after chemotherapy fails and has demonstrated the ability to nearly double patient survival rates.Why it mattersPancreatic cancer is one of the deadliest forms of cancer. The approval marks a significant milestone in the treatment of this disease, potentially transforming the standard of care for U.S. patients. For decades, a diagnosis of metas https://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-milestone-for-treatment-of-deadly-diseasehttps://www.live-feeds.com/feed/fda-approves-drug-for-pancreatic-cancer-in-milestone-for-treatment-of-deadly-disease#u49756Thu, 27 Aug 2026 08:00:35 +0000The FDA approved Rasonque, a once-daily pill from Revolution Medicines, for treating advanced pancreatic cancer on Wednesday, August 26, 2026. The drug targets the RAS protein, which drives 95% of pancreatic adenocarcinoma cases. Rasonque provides a treatment option for patients after chemotherapy fails and has demonstrated the ability to nearly double patient survival rates. This approval marks a significant milestone for one of the deadliest forms of cancer, potentially transforming the standard of care for U.S. patients.Why it mattersPancreatic adenocarcinoma is characterized by high mortal